Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
Ji Min KimBinnari KimEunji KimMinsun JangJun Hun ChoHye Seung LeeYoonjin KwakLingkang HuangRadha KrishnanSally Y BaiMounia MounawarKyoung-Mee KimPublished in: Molecular diagnosis & therapy (2022)
The PD-L1 22C3 antibody concentrate can potentially be used with the laboratory-developed test on three commercially available immunohistochemistry staining platforms to determine PD-L1 expression in tumor samples from patients with gastric or gastroesophageal junction adenocarcinoma.